• Publications
  • Influence
Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.
Dorzolamide demonstrated significant IOP lowering activity over 4 weeks and was well tolerated and there were no clinically significant changes in ocular or systemic safety parameters. Expand
The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis.
While the disability indices were more responsive to psoriasis characteristics than the HSQ SF-36 quality-of-life scales, all 8 HSQSF-36 dimensions demonstrated sensitivity to at least some objective and/or subjective ratings of severity, suggesting that the HSZ SF- 36 is sensitive to psychosocial suffering related to psOriasis, which is not conveyed in objective clinical measures of severity. Expand
.008% timolol ophthalmic solution. A minimal-effect dose in a normal volunteer model.
A double-masked, randomized, placebo-controlled, rising-dose, single-dose study was undertaken to assess the effect of low concentrations of timolol maleate ophthalmic solution (0.008%, 0.025%,Expand
Local tolerance and activity of MK-927, a novel topical carbonic anhydrase inhibitor.
Local tolerance of 2% MK-927 was acceptable and supports further clinical trials in patients and significant intraocular pressure-lowering activity was noted when comparing IOP four hours after first dose with that 20 hours predose in the treated eye of subjects receiving MK- 927. Expand
Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor.
Dorzolamide appears to have substantial potential in the treatment of glaucoma and ocular hypertension. Expand
MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors.
Topical carbonic anhydrase inhibitors MK-507 and sezolamide hydrochloride were compared in a double-masked, randomized, placebo-controlled study in 82 patients with bilateral primary open-angle glaucoma or ocular hypertension, and both drugs lowered intraocular pressure (IOP) substantially. Expand
MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action.
The dose response to a single topical administration of the carbonic anhydrase inhibitor MK-927 was investigated in 24 patients with primary open angle glaucoma or ocular hypertension and appeared to lower intraocular pressure in a dose-dependent fashion. Expand
Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin.
No significant differences were found among the groups in the frequencies of greater than or equal to 2-line worsening in visual acuity with concurrent progression in lenticular opacity, cataract extraction, or any spontaneously reported adverse ophthalmologic experience. Expand
A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients.
A single dose of MK-927 gave a clinically significant IOP reduction in patients, compared with a corresponding net change of 1.4 mmHg in the contralateral placebo treated eye. Expand
MK-927: a topically effective carbonic anhydrase inhibitor in patients.
The effects on intraocular pressure of the novel topical carbonic anhydrase inhibitor MK-927 were investigated for the first time in patients in a two-center, double-masked, randomized, placebo-controlled, two-period crossover study in patients with bilateral primary open angle glaucoma or ocular hypertension. Expand